Loading...
XLONVAL
Market cap1mUSD
Dec 24, Last price  
0.73GBP
1D
0.00%
1Q
-59.72%
Jan 2017
-99.89%
Name

ValiRx PLC

Chart & Performance

D1W1MN
XLON:VAL chart
P/E
—
P/S
9,995.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
94.28%
Rev. gr., 5y
%
Revenues
10k
00042,00031,0008,000177,000455,000216,269124,86887,55882,60300000009,600
Net income
-2m
L-15.31%
-150,000-345,000-134,000-1,240,000-1,856,000-1,443,000134,000-933,000-2,163,948-2,597,238-3,160,031-2,118,335-4,748,003-3,137,646-4,367,842-2,425,756-1,468,323-1,547,191-2,406,164-2,037,701
CFO
-2m
L+3.51%
74,000-225,000-63,000-839,000-794,000-926,000-496,000-1,461,000-1,980,412-2,067,660-3,007,171-2,590,088-4,216,068-2,351,433-3,353,509-1,341,663-1,910,717-1,260,572-1,712,245-1,772,351
Earnings
Jan 03, 2025

Profile

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
URL
https://www.valirx.com/
IPO date
Feb 28, 2000
Employees
8
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
10
 
Cost of revenue
2,307
2,278
1,749
Unusual Expense (Income)
NOPBT
(2,298)
(2,278)
(1,749)
NOPBT Margin
Operating Taxes
(175)
(193)
(133)
Tax Rate
NOPAT
(2,123)
(2,085)
(1,616)
Net income
(2,038)
-15.31%
(2,406)
55.52%
(1,547)
5.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,300
2,487
22
BB yield
Debt
Debt current
10
16
17
Long-term debt
12
28
55
Deferred revenue
Other long-term liabilities
Net debt
(153)
(1,094)
(522)
Cash flow
Cash from operating activities
(1,772)
(1,712)
(1,261)
CAPEX
(291)
Cash from investing activities
(306)
Cash from financing activities
1,116
2,256
7
FCF
(2,355)
(2,137)
(1,737)
Balance
Cash
175
1,137
594
Long term investments
Excess cash
174
1,137
594
Stockholders' equity
(24,967)
(24,186)
(22,316)
Invested Capital
27,893
28,033
25,784
ROIC
ROCE
EV
Common stock shares outstanding
101,570
77,302
65,005
Price
Market cap
EV
EBITDA
(2,044)
(2,066)
(1,520)
EV/EBITDA
Interest
4
5
3
Interest/NOPBT